Fig. 5

Depletion of MDSCs by anti-Gr1 can decrease HOXA7-induced KRAS mutant CRC metastasis. A–E In vivo administration of the anti-Gr1 neutralizing monoclonal antibody (clone RB6-8C5, 200 μg/mouse, i.p., every 3 days) or isotype control until the treatment endpoint in CT26-HOXA7 cells. Anti-Gr1 antibody treatment can significantly inhibit HOXA7-mediated KRAS mutant CRC metastasis. A Bioluminescence images and the incidence of lung and liver metastasis in the vehicle and anti-Gr1 groups. B Bioluminescence signals in each group. C Overall survival of the BALB/C mice in each group. D The numbers of lung and liver nodules. E HE staining was used to identify metastatic lung and liver nodules at 9 weeks. *P < 0.05